# Bioventus share price today (Bioventus Inc., BVS)

> Bioventus Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 0% of past readings. BVS · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/bvs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $10.95 (+67.2% in a year)
- P/E: 13.5× (lower than 100% of the last 1 year)
- Revenue (Jun 2026): $153 M (+3.8% on a year ago)
- Profit (Jun 2026): $36.2 M (+290.5% on a year ago)
- Operating margin: 12.2% (−0.2 points on a year ago)
- ROE: 12%, FY25
- ROIC: 11.6%, against a 7.3% cost of capital: +4.3 points
- Profit that came in as cash: 265%, last 2 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Bioventus share price today? Bioventus Inc.'s share price was $10.95 at the close on 3 November 2026. It has been rising for 25 weeks. That is 0.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $7 and $15, and at that close it sat 49% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 2 weeks running. Over the last 5.7 years the share price moved −36% while the S&P 500 moved +92%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Bioventus pay? Bioventus Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Bioventus on? Bioventus is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Bioventus profitable? Bioventus Inc. earned $36.2 M of net profit in the Jun 2026 quarter, +290.5% on the same quarter a year earlier. Full-year FY25 profit was $27.3 M. Over 4 years profit has grown 29.9% a year on average. That is 23.6% of the quarter's revenue. The same quarter a year earlier earned $9.3 M. 7 of the last 12 reported quarters were loss-making. ## How much revenue does Bioventus make, and is it growing? Bioventus Inc. reported $153 M of revenue in the Jun 2026 quarter, +3.8% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 7.2% a year on average. The last full year, FY25, came in at $568 M. The last four reported quarters add to $582 M. FY25 revenue was $568 M, −0.9% on the year before. Recent pace: the last four quarters grew +3.3% on average, against 7.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.1%, against +4.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Bioventus keep? Bioventus Inc.'s operating margin was 12.2% in the Jun 2026 quarter, 0.2 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −6.8% and 9.9%. The latest quarter is above every full year in that period. Across 5 years it has been between −6.8% and 9.9%, and FY25's 9.9% is the highest of them. Why the margin moved: operating margin changed −0.2 percentage points on the year while gross margin changed −0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Bioventus' profit turning into cash? Over the last 2 years, 265% of Bioventus Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $74.7 M of operating cash against $27.3 M of profit. After $2.6 M of spending on assets, $72.1 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Bioventus' cash go? Bioventus Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $10.9 M on assets over the last 3 years. Averaged over those years that is 0.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $10.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Bioventus' P/E ratio, and how does it compare with its own history? Bioventus Inc.'s P/E is 13.5×, about the lowest it has ever been. Its usual P/E (the middle reading) is 24.3×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bioventus business getting better or worse? Bioventus Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Bioventus earn on its capital? Bioventus Inc. earned a ROE of 12% in FY25. That is up from a low of −82% in FY23. Its return on capital used (ROIC) is 4.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 4.8% net margin and 0.83× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 4.8% net margin × 0.83× asset turnover × 2.99× leverage (assets divided by equity) ≈ 11.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 11.6% − 7.3% = +4.3 percentage points. The 7.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Bioventus have too much debt? Bioventus Inc. has total debt of $264 M against shareholder equity of $277 M as of Jun 2026, so its debt is 0.95× its equity. Year by year, that ratio went from 0.70 in FY21 to 1.36 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Bioventus shareholding pattern? 9.3% of Bioventus Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Bioventus from balance-sheet trouble? For Bioventus Inc., the Z-score is 1.75. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.75 is inside the danger zone, so the balance sheet is a real risk. ## How does Bioventus rank in its industry? There is no score against its industry: Bioventus Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Bioventus compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Bioventus in size? Bioventus is the 43rd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Integra LifeSciences Holdings Corporation, IRADIMED CORPORATION and QuidelOrtho Corporation. Just below it: AdaptHealth Corp., Beta Bionics, Inc. and OrthoPediatrics Corp. ### Medical Devices companies close in size

1. [Integra LifeSciences Holdings Corporation](https://www.sectoralpha.in/us/stocks/iart) $1.1 billion
2. [IRADIMED CORPORATION](https://www.sectoralpha.in/us/stocks/irmd) $1 billion
3. [QuidelOrtho Corporation](https://www.sectoralpha.in/us/stocks/qdel) $966 million
4. Bioventus Inc. $920 million
5. [AdaptHealth Corp.](https://www.sectoralpha.in/us/stocks/ahco) $838 million
6. [Beta Bionics, Inc.](https://www.sectoralpha.in/us/stocks/bbnx) $821 million
7. [OrthoPediatrics Corp.](https://www.sectoralpha.in/us/stocks/kids) $820 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Harmonic Inc.](https://www.sectoralpha.in/us/stocks/hlit) $1.1 billion · Communication Equipment
2. [Tripadvisor, Inc.](https://www.sectoralpha.in/us/stocks/trip) $1.1 billion · Travel Services
3. Bioventus Inc. $1.1 billion
4. [Wolfspeed, Inc.](https://www.sectoralpha.in/us/stocks/wolf) $1.1 billion · Semiconductors
5. [Dauch Corporation](https://www.sectoralpha.in/us/stocks/dch) $1.1 billion · Auto Parts

## What else do people ask about Bioventus? ### What were Bioventus's latest quarterly results? Bioventus Inc. reported revenue of $153 M and net profit of $36.2 M for the Jun 2026 quarter. Revenue rose 3.8% and profit rose 290.5% compared with a year earlier. Earnings per share were $0.47. The operating margin was 12.2%, 0.2 percentage points lower than a year earlier (as of 3 November 2026). ### What is Bioventus's market cap? Bioventus Inc.'s market capitalisation is $920 M at a stock price of $10.95. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bioventus performing? Bioventus Inc.'s share price has been rising for 25 weeks. In its latest quarter, revenue rose 3.8% and profit rose 290.5% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 2 weeks running (as of 3 November 2026). ### Will Bioventus's stock price go up? This page does not forecast Bioventus Inc.'s stock price. What it shows instead: the stock price is $10.95, and it has been rising for 25 weeks. Its P/E of 13.5× is higher than 0% of its own last 1 years (as of 3 November 2026). ### Does Bioventus have too much debt? Bioventus Inc. has a moderate amount of debt: its debt is 0.84× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Bioventus in its business cycle? Bioventus Inc.'s FY25 operating margin was 9.9%, against a 5-year range of −6.8% to 9.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 12.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bioventus story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bioventus a stock worth studying right now? What the numbers show: Bioventus Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 0% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.